Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Efficacy and safety of anrikefon in patients with pruritus undergoing haemodialysis: multicentre, double blind, randomised placebo controlled phase 3 trial.

Name: Kaimen Rigor review — Efficacy and safety of anrikefon in patients with pruritus undergoing haemodialysis: multicentre, double blind, randomised placebo controlled phase 3 trial.
Item: Efficacy and safety of anrikefon in patients with pruritus undergoing haemodialysis: multicentre, double blind, randomised placebo controlled phase 3 trial.
Rating: 96
Author: Alpha1

Liu BC, Li ZL, Zhang P, Zhong AM, Bai YL, Xu Y, Gao BH, Li YL, Wang Y, Zhou LH, Yao L, Wang JX, Yan R, Wang L, Liao B, Xie DQ, Yi XM, Guan TJ, Wang CL, Li GS, Li FQ, Chen JH, Anrikefon-302 study collaborator group

Paper source

Read full text (PMC)

Embed this Rigor badge

Kaimen Rigor review — 2.25★ (Weak), 0 critical, 3 high issues for “Efficacy and safety of anrikefon in patients with pruritus undergoing haemodialysis: multicentre, double blind, randomised placebo controlled phase 3 trial.”

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 15, 2026

Read alongside

Efficacy and safety of anrikefon in patients with pruritus undergoing haemodialysis: multicentre, double blind, randomised placebo controlled phase 3 trial.

Read full text (PMC)

DOI

10.1136/bmj-2025-085208

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/f9b1c096-33d8-4fcb-a3a0-382675a189b7" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/f9b1c096-33d8-4fcb-a3a0-382675a189b7/badge" alt="Kaimen Rigor review — 2.25★ (Weak), 0 critical, 3 high issues for “Efficacy and safety of anrikefon in patients with pruritus undergoing haemodialysis: multicentre, double blind, randomised placebo controlled phase 3 trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

782477466cb199440e7644f7b9df1dac183983098f44c2a08bec1b4b8afe06f6

Verify via API

Issued Aug 15, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Alpha¹ by Kaimen

Fetching the latest research

Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Efficacy and safety of anrikefon in patients with pruritus undergoing haemodialysis: multicentre, double blind, randomised placebo controlled phase 3 trial.

Paper source

Efficacy and safety of anrikefon in patients with pruritus undergoing haemodialysis: multicentre, double blind, randomised placebo controlled phase 3 trial.

Read full text (PMC)

Embed this Rigor badge

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 15, 2026

Kaimen Rigor review

Kaimen Rigor reviewed

2.25 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×3−1.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 6 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.
No data or code availability links were detected to verify.

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary endpoint is the WI-NRS score, a patient-reported symptom scale, which is a surrogate for the clinical outcome of pruritus. The paper does not provide evidence of target engagement at the tested dose (e.g., PK/PD data) nor does it cite validated evidence linking the WI-NRS score to a hard clinical outcome. The efficacy claim rests on this surrogate without such validation.
“The primary endpoint was the percentage of patients achieving at least a 4 point reduction in weekly mean 24 hour worst itching intensity numerical rating scale (WI-NRS) score from baseline to week 12.”
Find in source
02Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The primary effect is a 37% response rate in the anrikefon group versus 15% in placebo, with an odds ratio of 3.56. While statistically significant, the paper does not anchor this effect to a minimal clinically important difference or other clinical meaningfulness. The absolute difference is 22 percentage points, but no MCID is provided.
“37% of patients in the anrikefon group showed at least a 4 point reduction in WI-NRS score at week 12 compared with 15% in the placebo group (P<0.001).”
Find in source

Findings by category

101ArithmeticNumerical inconsistencies 302OverreachOverstated conclusions 03AuthenticityNone found 104DisclosureReporting gaps 05AvailabilityNone found · partly checked 06Copyedit6 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and well-reported phase 3 randomised controlled trial with strong methodological rigor across most dimensions. The main weaknesses are the absence of a data availability statement and several minor internal inconsistencies in reported numbers that warrant correction.

Both reviewers classified the study as interventional and agreed on all dimension statuses. The statistics verification component recomputed only 4 of the reported tests/effect estimates (all consistent); the remaining statistics were not machine-verified. The copyedit pass flagged minor internal inconsistencies in participant counts and percentages.

Numerical inconsistencies

1 finding · worst low

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Recomputed 4 tests: 4 consistent, 0 inconsistent; 4 via agent-written checks.

Overstated conclusions

3 findings · worst high

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

7 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Data authenticity concerns

None found

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Checked — nothing surfaced.

Reporting gaps

1 finding · worst medium

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

Eight Dimensions7 pass · 1 warn

The paper cites prior work on the prevalence and impact of CKD-associated pruritus, the role of kappa/mu opioid receptor imbalance, and a previous phase 2 trial of anrikefon showing clinically meaningful reductions in itch intensity. The rationale logically links the premise to the study objectives, and the limitations of prior research (e.g., need for phase 3 confirmation) are addressed by conducting this trial.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The introduction establishes a clear scientific rationale for the study, citing prior research on CKD-associated pruritus and kappa opioid receptor agonists, and identifies the gap addressed by the phase 3 trial.

Evidence

“A previous phase 2 trial involving patients receiving haemodialysis and with moderate to severe pruritus showed clinically meaningful reductions in itch intensity and statistically significant improvements in itch related quality of life in the anrikefon group compared with placebo group.”

Introduction ¶1Find in source

“Notably, the imbalance between kappa opioid receptor and mu opioid receptor signalling is considered to play a crucial role in the development of pruritus.”

Introduction ¶2Find in source

“We conducted a phase 3 trial to evaluate the efficacy and safety of anrikefon in patients with moderate to severe pruritus undergoing haemodialysis.”

Introduction ¶3Find in source

PASSReviewer 2· 90% conf

The introduction establishes the clinical burden of CKD-associated pruritus, the rationale for kappa opioid receptor agonism, and prior phase 2 evidence, with limitations of prior work acknowledged.

Evidence

“CKD associated pruritus affects more than 60% of patients undergoing haemodialysis, with 33-50% reporting moderate to severe itching.”

Introduction ¶1Find in source

“the imbalance between kappa opioid receptor and mu opioid receptor signalling is considered to play a crucial role in the development of pruritus.”

Introduction ¶2Find in source

“A previous phase 2 trial involving patients receiving haemodialysis and with moderate to severe pruritus showed clinically meaningful reductions in itch intensity”

Introduction ¶3Find in source

Randomisation used a computer-generated sequence with stratification by baseline WI-NRS score. Blinding is described (double-blind). A sample size calculation was performed based on phase 2 data, with a one-sided test, alpha 0.025, power 80%, and a 20% dropout adjustment. Inclusion/exclusion criteria are described, and the analysis population (full analysis set) and missing data handling (multiple imputation) are pre-specified. The trial is a human RCT, so replicate_distinction, controls, and independent_replication are not applicable.

Sub-criteria

controlsN/A

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous: randomised, double-blind, placebo-controlled, with a pre-specified sample size calculation, stratification, and a clear analysis population.

Evidence

“Randomisation and blinding were performed using a computer generated sequence and stratified by baseline WI-NRS score (<7 (moderate itching) and ≥7 (severe itching)) to ensure that the groups were well balanced for disease severity.”

MethodsFind in source

“Using a one sided test with a significance level of 0.025 and a power of 80%, a total of 434 participants were required to detect a difference in the primary endpoint. Considering a 20% dropout rate, we aimed to enrol study 544 participants.”

Statistical analysisFind in source

“Eligible patients for the double blind phase were adults (≥18 years) undergoing haemodialysis three times weekly for at least three months, with a dry body weight (ie, patients neither overhydrated or underhydrated, as determined by the doctor) of 40-135 kg and moderate to severe pruritus.”

Statistical analysisFind in source

PASSReviewer 2· 95% conf

The trial is a well-designed randomised, double-blind, placebo-controlled phase 3 trial with adequate randomisation, blinding, sample size justification, and pre-specified analysis populations.

Evidence

“Randomisation and blinding were performed using a computer generated sequence and stratified by baseline WI-NRS score (<7 (moderate itching) and ≥7 (severe itching))”

MethodsFind in source

“Using a one sided test with a significance level of 0.025 and a power of 80%, a total of 434 participants were required to detect a difference in the primary endpoint.”

Statistical analysisFind in source

“data handling according to the multiple imputation strategy for missing data”

Statistical analysisFind in source

The study reports sex (70% men), mean age (52.7 years), and baseline WI-NRS scores. Since both sexes are enrolled, sex_justified is not applicable. Age, weight, and health status are reported in Table 1. Demographics are adequately reported. Species/strain and housing conditions are not applicable for a human trial.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Demographic and clinical characteristics are well reported, including sex, age, and baseline disease severity.

Evidence

“The study population comprised predominantly men (70%), with a mean age of 52.7 years.”

ResultsFind in source

paraphrase[Table 1]

“Sex: Men 195 (71) | 185 (69); Women 80 (29) | 84 (31)”

PASSReviewer 2· 90% conf

Demographic and clinical characteristics are well reported, including sex, age, and baseline disease severity.

Evidence

paraphrase[Table 1]

“Men 195 (71) | 185 (69)”

paraphrase[Table 1]

“Mean (SD) 51.8 (10.7) | 53.6 (11.2)”

“The baseline weekly mean WI-NRS score was 7.0 (standard deviation (SD 1.1).”

ResultsFind in source

The paper states approval by the ethics committee of the Clinical Research of the First Affiliated Hospital to Zhejiang University School of Medicine (approval No 2022-177), Zhongda Hospital Affiliated to Southeast University School of Medicine (approval No 2021ZDSYLL318-Y01), and all other participating centres. Written informed consent was obtained from all participants. Compliance with the Declaration of Helsinki and Good Clinical Practice guidelines is stated.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethical approval from named ethics committees and written informed consent are documented.

Evidence

“This study was approved by the ethics committee of the Clinical Research of the First Affiliated Hospital to Zhejiang University School of Medicine (approval No 2022-177), Zhongda Hospital Affiliated to Southeast University School of Medicine (approval No 2021ZDSYLL318-Y01), and all other participating centres.”

EthicsFind in source

“All participants provided written informed consent before trial participation.”

EthicsFind in source

“This trial was also conducted in accordance with the principles of the Declaration of Helsinki and the Good Clinical Practice guidelines.”

EthicsFind in source

PASSReviewer 2· 95% conf

Ethical approval from named ethics committees and written informed consent are documented, along with compliance with the Declaration of Helsinki and GCP.

Evidence

EthicsFind in source

“All participants provided written informed consent before trial participation.”

EthicsFind in source

“This trial was also conducted in accordance with the principles of the Declaration of Helsinki and the Good Clinical Practice guidelines.”

EthicsFind in source

Anrikefon is named as the investigational drug, with dose (0.3 μg/kg) and regimen (three times weekly). The manufacturer (Haisco Pharmaceutical Group) is mentioned in funding. Statistical software (SAS version 9.4) is identified. Other bench resources (antibodies, cell lines, etc.) are not applicable.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

The investigational product (anrikefon) is identified with dose and regimen; statistical software is identified.

Evidence

“Intravenous anrikefon (0.3 μg/kg body weight) or placebo three times weekly for 12 weeks”

AbstractFind in source

“All statistical analyses were performed using SAS software (version 9.4).”

Statistical analysisFind in source

PASSReviewer 2· 85% conf

The investigational product (anrikefon) is identified by name and dose, and the statistical software is identified; no other biological/chemical resources are applicable.

Evidence

“Intravenous anrikefon (0.3 μg/kg body weight) or placebo three times weekly for 12 weeks”

AbstractFind in source

“All statistical analyses were performed using SAS software (version 9.4).”

Statistical analysisFind in source

The primary analysis uses logistic regression with multiple imputation, and secondary endpoints use mixed effects models. Tests are named (χ² test, analysis of covariance). Exact p-values are reported (e.g., P<0.001). Effect sizes with confidence intervals are provided. Software is identified. Data presentation includes per-group n and confidence intervals. Mathematical plausibility checks are not applicable due to large sample size and continuous outcomes.

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical methods are appropriate and well described, with exact p-values and confidence intervals reported.

Evidence

“For each imputed complete dataset, a logistic regression model was applied, using at least a 4 point change from baseline to week 12 in the weekly mean WI-NRS score as the dependent variable, the treatment group as the independent variable, and the baseline WI-NRS score as a covariate.”

Statistical analysisFind in source

paraphrase[Results, Primary endpoint]

“The odds ratio for the anrikefon group versus placebo group was 3.56 (95% CI 2.30 to 5.50), with a P<0.001.”

“P values were calculated using χ 2 test (A and B) and analysis of covariance (C and D).”

Figure 3Find in source

PASSReviewer 2· 90% conf

Statistical methods are appropriate and well described, with exact p-values and confidence intervals reported; no arithmetic inconsistencies found.

Evidence

“For each imputed complete dataset, a logistic regression model was applied”

Statistical analysisFind in source

“with a P<0.001”

ResultsFind in source

“The odds ratio for the anrikefon group versus placebo group was 3.56 (95% CI 2.30 to 5.50)”

ResultsFind in source

The paper does not include an explicit data availability statement in the main text. The supplementary appendix is mentioned but not a repository. No accession numbers or code repository are provided. For a clinical trial, managed access is acceptable, but the absence of any statement is a gap.

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositNOT REPORTED

data availability statementNOT REPORTED

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 80% conf

A data availability statement is present but vague, and no data repository or code sharing is mentioned.

Evidence

absence[Entire paper]

No data availability statement found.

WARNReviewer 2· 80% conf

A data availability statement is present but vague, and no data repository or code sharing is mentioned.

Evidence

absence[Entire paper]

No data availability statement found.

“The lead author (the manuscript’s guarantor) affirms that the manuscript is an honest, accurate, and transparent account of the study being reported”

Transparency sectionFind in source

Trial registration number is provided (NCT05135390). Methods are comprehensive. Limitations are explicitly discussed. Conclusions are proportional to the evidence. Funding and competing interests are declared. No reporting guideline checklist is mentioned, but this is not a fail.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineNOT REPORTED

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The trial is registered, methods are detailed, limitations are discussed, and funding/COI are disclosed.

Evidence

“Trial registration ClinicalTrials.gov NCT05135390 .”

AbstractFind in source

“This study has several limitations. Firstly, it exclusively enrolled patients with end stage renal disease requiring haemodialysis.”

LimitationsFind in source

“Funding: This trial was funded by the Haisco Pharmaceutical Group.”

FundingFind in source

PASSReviewer 2· 90% conf

The trial is registered, methods are detailed, limitations are discussed, and funding/COI are disclosed.

Evidence

“ClinicalTrials.gov NCT05135390”

AbstractFind in source

“This study has several limitations. Firstly, it exclusively enrolled patients with end stage renal disease requiring haemodialysis.”

LimitationsFind in source

“This trial was funded by the Haisco Pharmaceutical Group.”

FundingFind in source

Registered (1 ID: ClinicalTrials.gov). No reporting guideline cited.

Broken references and links

None found · partly checked

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Nothing surfaced — but not everything feeding this category ran (missing: data/code link verification), so read this as a partial clean bill.

Checked 26 references by DOI: 24 verified — 2 no DOI (shown, not verified).

Copyediting

6 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 6 minor suggestions below.

6 copyedit issues flagged: mostly consistency, clarity, typo.

Kaimen Rigor Action ItemsFinal pass before journal submission

The published work is robust in design and reporting, but readers should weigh the missing data availability statement and the minor internal inconsistencies (e.g., adverse event percentage, open-label participant count) as limitations. These issues do not undermine the primary efficacy findings but warrant clarification or an erratum.

1.
HIGHdata code
Add a data availability statement in the 'Transparency' section specifying how de-identified participant data can be accessed (e.g., via a data access committee or repository) with conditions and timeframe.
The absence of a data availability statement is a reporting gap that limits reproducibility and transparency.
2.
HIGHstatistics
Correct the internal inconsistency in the adverse events sentence: 'The incidence of severe treatment emergent adverse events (CTCAE grade ≥3) was 42%, affecting four participants (1%)' — clarify the denominator and correct the percentage or the count.
The current statement is internally contradictory (42% of 442 is ~186, not 4) and could mislead readers.
3.
HIGHreporting
Reconcile the open-label phase participant count: the abstract states 443 entered the open-label extension, but Table 3 lists n=442; correct the discrepancy.
Inconsistent participant counts across sections undermine confidence in the reported data.
4.
MEDIUMreporting
Correct the rounding discrepancy in the abstract: 243/275 (88%) should be 242/275 (88%) or adjust the numerator to match the percentage.
Minor arithmetic inconsistency in a headline completion rate.
5.
MEDIUMreporting
Clarify the overall mean age in the Results text (52.7 years) versus Table 1 group means (51.8 and 53.6) by stating it is a weighted average or correcting the text.
Readers may question the consistency of reported demographic data.
6.
MEDIUMreporting
Mention adherence to CONSORT reporting guidelines in the methods or acknowledgements, and consider submitting the CONSORT checklist as supplementary material.
Explicitly following a reporting guideline enhances transparency and completeness.
7.
MEDIUMdata code
Consider depositing the statistical analysis code (e.g., SAS code) in a public repository like Zenodo or GitHub with a DOI to enhance reproducibility.
Sharing analysis code allows independent verification of the statistical methods.
8.
MEDIUMreporting
Clarify the role of the funder in the trial design, conduct, analysis, and reporting, as the current funding statement is brief.
Transparency about funder involvement is important for assessing potential bias.
9.
LOWreporting
Provide more detail on the open-label extension phase's analysis methods, including how missing data were handled and the statistical model used for the 5-D itch scale at week 40.
Additional methodological detail would improve the completeness of the report.
10.
LOWcopyedit
Format author names and affiliations consistently in the author list (e.g., 'Liu Bi-Cheng professor Li Zuo-Lin consultant nephrologist' should be separated).
Consistent formatting improves professionalism and readability.

Full text (39,798 chars)Analyzed: Aug 15, 2026

Start the discussion on JRNLClub

Community discussion on jrnlclub.com

Read alongside

Efficacy and safety of anrikefon in patients with pruritus undergoing haemodialysis: multicentre, double blind, randomised placebo controlled phase 3 trial.

Read full text (PMC)

DOI

10.1136/bmj-2025-085208

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/f9b1c096-33d8-4fcb-a3a0-382675a189b7" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/f9b1c096-33d8-4fcb-a3a0-382675a189b7/badge" alt="Kaimen Rigor review — 2.25★ (Weak), 0 critical, 3 high issues for “Efficacy and safety of anrikefon in patients with pruritus undergoing haemodialysis: multicentre, double blind, randomised placebo controlled phase 3 trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

782477466cb199440e7644f7b9df1dac183983098f44c2a08bec1b4b8afe06f6

Verify via API

Issued Aug 15, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Kaimen Rigor review

Kaimen Rigor reviewed

2.25 / 5

Weak — serious problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×3−1.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 6 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.
No data or code availability links were detected to verify.

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary endpoint is the WI-NRS score, a patient-reported symptom scale, which is a surrogate for the clinical outcome of pruritus. The paper does not provide evidence of target engagement at the tested dose (e.g., PK/PD data) nor does it cite validated evidence linking the WI-NRS score to a hard clinical outcome. The efficacy claim rests on this surrogate without such validation.
“The primary endpoint was the percentage of patients achieving at least a 4 point reduction in weekly mean 24 hour worst itching intensity numerical rating scale (WI-NRS) score from baseline to week 12.”
Find in source
02Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The primary effect is a 37% response rate in the anrikefon group versus 15% in placebo, with an odds ratio of 3.56. While statistically significant, the paper does not anchor this effect to a minimal clinically important difference or other clinical meaningfulness. The absolute difference is 22 percentage points, but no MCID is provided.
“37% of patients in the anrikefon group showed at least a 4 point reduction in WI-NRS score at week 12 compared with 15% in the placebo group (P<0.001).”
Find in source

Findings by category

101ArithmeticNumerical inconsistencies 302OverreachOverstated conclusions 03AuthenticityNone found 104DisclosureReporting gaps 05AvailabilityNone found · partly checked 06Copyedit6 minor suggestions

Numerical inconsistencies

1 finding · worst low

Internal contradictions in the reported numbersAssessed

Recomputed 4 tests: 4 consistent, 0 inconsistent; 4 via agent-written checks.

Overstated conclusions

3 findings · worst high

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

7 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Data authenticity concerns

None found

Checked — nothing surfaced.

Reporting gaps

1 finding · worst medium

Data/code availability incompleteAssessed

Eight Dimensions7 pass · 1 warn

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Evidence

Introduction ¶1Find in source

“Notably, the imbalance between kappa opioid receptor and mu opioid receptor signalling is considered to play a crucial role in the development of pruritus.”

Introduction ¶2Find in source

“We conducted a phase 3 trial to evaluate the efficacy and safety of anrikefon in patients with moderate to severe pruritus undergoing haemodialysis.”

Introduction ¶3Find in source

PASSReviewer 2· 90% conf

The introduction establishes the clinical burden of CKD-associated pruritus, the rationale for kappa opioid receptor agonism, and prior phase 2 evidence, with limitations of prior work acknowledged.

Evidence

“CKD associated pruritus affects more than 60% of patients undergoing haemodialysis, with 33-50% reporting moderate to severe itching.”

Introduction ¶1Find in source

“the imbalance between kappa opioid receptor and mu opioid receptor signalling is considered to play a crucial role in the development of pruritus.”

Introduction ¶2Find in source

“A previous phase 2 trial involving patients receiving haemodialysis and with moderate to severe pruritus showed clinically meaningful reductions in itch intensity”

Introduction ¶3Find in source

Sub-criteria

controlsN/A

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous: randomised, double-blind, placebo-controlled, with a pre-specified sample size calculation, stratification, and a clear analysis population.

Evidence

MethodsFind in source

Statistical analysisFind in source

PASSReviewer 2· 95% conf

The trial is a well-designed randomised, double-blind, placebo-controlled phase 3 trial with adequate randomisation, blinding, sample size justification, and pre-specified analysis populations.

Evidence

“Randomisation and blinding were performed using a computer generated sequence and stratified by baseline WI-NRS score (<7 (moderate itching) and ≥7 (severe itching))”

MethodsFind in source

“Using a one sided test with a significance level of 0.025 and a power of 80%, a total of 434 participants were required to detect a difference in the primary endpoint.”

Statistical analysisFind in source

“data handling according to the multiple imputation strategy for missing data”

Statistical analysisFind in source

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Demographic and clinical characteristics are well reported, including sex, age, and baseline disease severity.

Evidence

“The study population comprised predominantly men (70%), with a mean age of 52.7 years.”

ResultsFind in source

paraphrase[Table 1]

“Sex: Men 195 (71) | 185 (69); Women 80 (29) | 84 (31)”

PASSReviewer 2· 90% conf

Demographic and clinical characteristics are well reported, including sex, age, and baseline disease severity.

Evidence

paraphrase[Table 1]

“Men 195 (71) | 185 (69)”

paraphrase[Table 1]

“Mean (SD) 51.8 (10.7) | 53.6 (11.2)”

“The baseline weekly mean WI-NRS score was 7.0 (standard deviation (SD 1.1).”

ResultsFind in source

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethical approval from named ethics committees and written informed consent are documented.

Evidence

EthicsFind in source

“All participants provided written informed consent before trial participation.”

EthicsFind in source

“This trial was also conducted in accordance with the principles of the Declaration of Helsinki and the Good Clinical Practice guidelines.”

EthicsFind in source

PASSReviewer 2· 95% conf

Ethical approval from named ethics committees and written informed consent are documented, along with compliance with the Declaration of Helsinki and GCP.

Evidence

EthicsFind in source

“All participants provided written informed consent before trial participation.”

EthicsFind in source

“This trial was also conducted in accordance with the principles of the Declaration of Helsinki and the Good Clinical Practice guidelines.”

EthicsFind in source

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

The investigational product (anrikefon) is identified with dose and regimen; statistical software is identified.

Evidence

“Intravenous anrikefon (0.3 μg/kg body weight) or placebo three times weekly for 12 weeks”

AbstractFind in source

“All statistical analyses were performed using SAS software (version 9.4).”

Statistical analysisFind in source

PASSReviewer 2· 85% conf

The investigational product (anrikefon) is identified by name and dose, and the statistical software is identified; no other biological/chemical resources are applicable.

Evidence

“Intravenous anrikefon (0.3 μg/kg body weight) or placebo three times weekly for 12 weeks”

AbstractFind in source

“All statistical analyses were performed using SAS software (version 9.4).”

Statistical analysisFind in source

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical methods are appropriate and well described, with exact p-values and confidence intervals reported.

Evidence

Statistical analysisFind in source

paraphrase[Results, Primary endpoint]

“The odds ratio for the anrikefon group versus placebo group was 3.56 (95% CI 2.30 to 5.50), with a P<0.001.”

“P values were calculated using χ 2 test (A and B) and analysis of covariance (C and D).”

Figure 3Find in source

PASSReviewer 2· 90% conf

Statistical methods are appropriate and well described, with exact p-values and confidence intervals reported; no arithmetic inconsistencies found.

Evidence

“For each imputed complete dataset, a logistic regression model was applied”

Statistical analysisFind in source

“with a P<0.001”

ResultsFind in source

“The odds ratio for the anrikefon group versus placebo group was 3.56 (95% CI 2.30 to 5.50)”

ResultsFind in source

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositNOT REPORTED

data availability statementNOT REPORTED

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 80% conf

A data availability statement is present but vague, and no data repository or code sharing is mentioned.

Evidence

absence[Entire paper]

No data availability statement found.

WARNReviewer 2· 80% conf

A data availability statement is present but vague, and no data repository or code sharing is mentioned.

Evidence

absence[Entire paper]

No data availability statement found.

“The lead author (the manuscript’s guarantor) affirms that the manuscript is an honest, accurate, and transparent account of the study being reported”

Transparency sectionFind in source

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineNOT REPORTED

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The trial is registered, methods are detailed, limitations are discussed, and funding/COI are disclosed.

Evidence

“Trial registration ClinicalTrials.gov NCT05135390 .”

AbstractFind in source

“This study has several limitations. Firstly, it exclusively enrolled patients with end stage renal disease requiring haemodialysis.”

LimitationsFind in source

“Funding: This trial was funded by the Haisco Pharmaceutical Group.”

FundingFind in source

PASSReviewer 2· 90% conf

The trial is registered, methods are detailed, limitations are discussed, and funding/COI are disclosed.

Evidence

“ClinicalTrials.gov NCT05135390”

AbstractFind in source

“This study has several limitations. Firstly, it exclusively enrolled patients with end stage renal disease requiring haemodialysis.”

LimitationsFind in source

“This trial was funded by the Haisco Pharmaceutical Group.”

FundingFind in source

Registered (1 ID: ClinicalTrials.gov). No reporting guideline cited.

Broken references and links

None found · partly checked

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Nothing surfaced — but not everything feeding this category ran (missing: data/code link verification), so read this as a partial clean bill.

Checked 26 references by DOI: 24 verified — 2 no DOI (shown, not verified).

Copyediting

6 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 6 minor suggestions below.

6 copyedit issues flagged: mostly consistency, clarity, typo.

Kaimen Rigor Action ItemsFinal pass before journal submission

1.
HIGHdata code
Add a data availability statement in the 'Transparency' section specifying how de-identified participant data can be accessed (e.g., via a data access committee or repository) with conditions and timeframe.
The absence of a data availability statement is a reporting gap that limits reproducibility and transparency.
2.
HIGHstatistics
Correct the internal inconsistency in the adverse events sentence: 'The incidence of severe treatment emergent adverse events (CTCAE grade ≥3) was 42%, affecting four participants (1%)' — clarify the denominator and correct the percentage or the count.
The current statement is internally contradictory (42% of 442 is ~186, not 4) and could mislead readers.
3.
HIGHreporting
Reconcile the open-label phase participant count: the abstract states 443 entered the open-label extension, but Table 3 lists n=442; correct the discrepancy.
Inconsistent participant counts across sections undermine confidence in the reported data.
4.
MEDIUMreporting
Correct the rounding discrepancy in the abstract: 243/275 (88%) should be 242/275 (88%) or adjust the numerator to match the percentage.
Minor arithmetic inconsistency in a headline completion rate.
5.
MEDIUMreporting
Clarify the overall mean age in the Results text (52.7 years) versus Table 1 group means (51.8 and 53.6) by stating it is a weighted average or correcting the text.
Readers may question the consistency of reported demographic data.
6.
MEDIUMreporting
Mention adherence to CONSORT reporting guidelines in the methods or acknowledgements, and consider submitting the CONSORT checklist as supplementary material.
Explicitly following a reporting guideline enhances transparency and completeness.
7.
MEDIUMdata code
Consider depositing the statistical analysis code (e.g., SAS code) in a public repository like Zenodo or GitHub with a DOI to enhance reproducibility.
Sharing analysis code allows independent verification of the statistical methods.
8.
MEDIUMreporting
Clarify the role of the funder in the trial design, conduct, analysis, and reporting, as the current funding statement is brief.
Transparency about funder involvement is important for assessing potential bias.
9.
LOWreporting
Provide more detail on the open-label extension phase's analysis methods, including how missing data were handled and the statistical model used for the 5-D itch scale at week 40.
Additional methodological detail would improve the completeness of the report.
10.
LOWcopyedit
Format author names and affiliations consistently in the author list (e.g., 'Liu Bi-Cheng professor Li Zuo-Lin consultant nephrologist' should be separated).
Consistent formatting improves professionalism and readability.

Full text (39,798 chars)Analyzed: Aug 15, 2026